Pleomorphic Dermal Sarcoma

Jasmine S Saleh; Carli P Whittington; Scott C Bresler; Rajiv M Patel

doi:10.1016/j.path.2023.06.007

Pleomorphic Dermal Sarcoma

Surg Pathol Clin. 2024 Mar;17(1):153-158. doi: 10.1016/j.path.2023.06.007. Epub 2023 Aug 5.

Authors

Jasmine S Saleh¹, Carli P Whittington¹, Scott C Bresler¹, Rajiv M Patel²

Affiliations

¹ Department of Pathology, University of Michigan, 2800 Plymouth Road, Building 35, Ann Arbor, MI 48109, USA; Department of Dermatology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA.
² Department of Pathology, University of Michigan, 2800 Plymouth Road, Building 35, Ann Arbor, MI 48109, USA; Department of Dermatology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109, USA; Cutaneous Pathology, WCP Laboratories, Inc., Maryland Heights, MO, USA. Electronic address: [email protected].

PMID: 38278604
DOI: 10.1016/j.path.2023.06.007

Abstract

Pleomorphic dermal sarcoma (PDS) is a rare cutaneous/subcutaneous neoplasm of purported mesenchymal differentiation that exists along a clinicopathologic spectrum with atypical fibroxanthoma (AFX). While PDS and AFX share histopathologic and immunohistochemical features, PDS exhibits deeper tissue invasion and has a higher rate of metastasis and local recurrence than AFX. Given its aggressive clinical course, early recognition and clinical management of PDS are essential for optimizing patient outcomes. This review aims to provide a brief overview of the clinicopathologic and molecular features, prognosis, and treatment of PDS.

Keywords: Atypical fibroxanthoma; Malignant fibrous histiocytoma; Pleomorphic dermal sarcoma; Sarcoma; Undifferentiated pleomorphic sarcoma.

Publication types

Review

MeSH terms

Histiocytoma, Malignant Fibrous* / pathology
Humans
Prognosis
Sarcoma* / diagnosis
Sarcoma* / genetics
Sarcoma* / pathology
Skin Neoplasms* / diagnosis
Skin Neoplasms* / genetics
Skin Neoplasms* / pathology